News | Radiopharmaceuticals and Tracers | June 20, 2016

Pretargeted Radioimmunotherapy May Eliminate Colorectal Cancer

Antibody and radionuclide drug combo provides a cure in preclinical colorectal cancer research

pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

June 20, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.

Theranostic drugs are powerful newcomers in oncology’s arsenal. In addition to providing targeted treatment, in many cases they double as imaging agents that can monitor the effectiveness of therapy.

An investigative treatment called pretargeted radioimmunotherapy (PRIT) is harnessing an antibody that attaches to the cell-surface antigen glycoprotein A33, which is hyper-expressed in the vast majority of colon cancers, whether primary or metastatic. Researchers united the anti-GPA33 antibody with radionuclide agents that deliver a powerful dose of radiation directly to the tumor. The technique was found to be entirely curative in this preliminary mouse study.

“If these results can be replicated in prospective human studies, this multi-platform approach could be used with an array of antibodies to treat a number of cancers, especially colorectal and ovarian cancers,” said Sarah M. Cheal, Ph.D., the presenting author from Memorial Sloan Kettering Cancer Center, New York, N.Y.

For this study, researchers tested the efficacy of anti-GPA33 with radiotherapies using lutetium-177 benzylDOTA (Lu-177 DOTA-Bn) in mice bearing colorectal cancer grafts. In the same group of animals, the researchers were able to detect solid tumors of 10 milligrams or less during the course of a fractionated treatment regimen that achieved complete cures in all solid tumors without any collateral toxicity. This platform of theranostic radioimmunotherapy could have broad applicability. Cheal estimates that, if validated, these cancer-fighting techniques could be made available in as few as five years.

According to the most current statistics from the American Cancer Society, an estimated 71,830 American men and 65,000 women will be diagnosed with colorectal cancer in 2016. Approximately 26,270 men and 24,040 women are expected to die from the disease.

For more information: www.snmmi.org

Related Content

IBA Installs Three Proteus One Systems in One Week
News | Proton Therapy | April 28, 2017
April 28, 2017 — IBA announced the delivery and rigging of three Proteus One treatment rooms in less than a week at c
Nottingham City Hospital Selects RayStation for Radiotherapy Treatment Planning
News | Treatment Planning | April 28, 2017
Nottingham City Hospital in the United Kingdom has chosen RayStation as the new treatment planning system for its...
IBA Dosimetry Americas Announces New Exclusive Canadian Distributor for Radiotherapy Products
News | Radiation Therapy | April 28, 2017
April 28, 2017 — IBA (Ion Beam Applications S.A.) announced the Dosimetry Americas division has recently partnered wi
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
Early Stereotactic Radiosurgery Improves Outcomes for Nonfunctioning Pituitary Macroadenoma Patients
News | Radiation Therapy | April 27, 2017
Jason P. Sheehan, M.D., Ph.D., FAANS, winner of the Leksell Radiosurgery Award, presented his research on stereotactic...
Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium
News | Radiation Therapy | April 26, 2017
April 26, 2017 — The National Comprehensive Cancer Network (NCCN) continues to build its NCCN Radiation Therapy Compe
Precision Medicine Poised to Change Brain Tumor Diagnostics and Treatment
News | Radiation Therapy | April 26, 2017
April 26, 2017 — A new report on the brain cancer diagnostics market projects that up to 78,000 new cases of primary
Elekta Highlights Leksell Vantage System for Stereotactic Neurosurgery at AANS 2017
News | Radiation Therapy | April 24, 2017
Elekta announced that its Leksell Vantage Stereotactic System, will be highlighted at the American Association of...
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
Overlay Init